NCT06060613招募中1 期
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 208
- 试验地点
- 19
- 主要终点
- Incidence and nature of dose-limiting toxicities (DLTs)
研究概览
简要总结
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
详细描述
Primary Objective (Phase 1):
• Assess the safety and tolerability of OBX-115 regimen
Primary Objective (Phase 2):
- Evaluate preliminary efficacy of OBX-115 regimen as measured by Blinded Independent Central Review (BICR) using objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Cohort 3)
- Evaluate preliminary efficacy of OBX-115 regimen as measured by the investigator using objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Cohorts 1, 2, 4)
Secondary (Phase 1):
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be 18 years of age or older at the time of signing the informed consent.
- •Participant has a histologically confirmed diagnosis of advanced/metastatic melanoma or relapsed refractory metastatic non-small cell lung cancer (NSCLC).
- •Cohort and indication specific criteria as follows:
- •Phase 1 and Phase 2 Cohort 1 (enrollment complete):
- •Participants with unresectable or metastatic melanoma must have experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blocking antibody.
- •Participants with melanoma must not exceed 2 prior lines of systemic therapy. Neoadjuvant/Adjuvant treatment will not be considered a prior line of systemic therapy unless the participant progressed during or within the 12 weeks after the last dose of the adjuvant PD-1/PD-L1 blocking antibody.
- •Phase 1 and Phase 2 Cohort 2 (recruiting):
- •Participants with non-small cell lung cancer should have relapsed or are refractory to approved systemic therapies (approved ICI-based regimen for all appropriate participants and/or an approved targeted therapy for known molecular abnormalities if applicable to their disease).
- •Participant must not have been exposed to any second line cytotoxic chemotherapy if they have already received cytotoxic chemotherapy in the first line setting.
- •Phase 2 Cohort 3 (recruiting):
- •Participants with unresectable or metastatic melanoma must have experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blocking antibody.
- •Participants with melanoma must not exceed 2 prior lines of systemic therapy. Neoadjuvant/Adjuvant treatment will not be considered a prior line of systemic therapy unless the participant progressed during or within the 12 weeks after the last dose of the adjuvant PD-1/PD-L1 blocking antibody.
- •Participants with targetable BRAF mutations are not required to have received prior BRAF inhibitors. Participants must not have disease progression on a BRAF/MEK inhibitor that was given as the most recent line of therapy.
- •Phase 2 Cohort 4 (recruiting):
- •Participants with frontline unresectable or metastatic melanoma.
- •Participants may have received up to 2 doses of system therapy containing a programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blocking antibody-based treatment of unresectable metastatic melanoma (but must not have known clinical progression.) Neoadjuvant/Adjuvant treatment will not be considered a prior line of systemic therapy; however, participants whose disease progressed within 12 weeks after the last dose of the PD-1/PD-L1 blocking antibody given as adjuvant treatment (primary ICI resistant) are not eligible.
- •Participant is assessed as having at least one lesion (or aggregate lesions) suitable for OBX-115 generation.
- •After tumor tissue procurement, the participant will have at least one remaining measurable lesion, as defined by RECIST v1.
- •Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of greater than 6 months.
- •Participant has recovered from all prior anticancer treatment-related AEs to at least Grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE]).
- •Participants must have completed post-operative recovery from any prior surgical procedures with wound healing and resolution of all surgical complications prior to planned tumor procurement surgery.
- •Both male and female (women of childbearing potential) participants agree to the follow protocol specified contraceptive and/or abstinence requirements.
- •Participant has protocol specified hematologic parameters for absolute neutrophil count (ANC) and platelet count.
- •Participant has adequate cardiac, liver, lung, and kidney organ function as specified in the protocol.
排除标准
- •Participant has melanoma of uveal origin or its other genetic equivalents (e.g. GNA11 and GNAQ).
- •Participant has a history of brain metastases or leptomeningeal disease. Participants may be considered for enrollment if they have 4 or fewer brain metastatic lesions that are that have been treated, if clinically indicated. Asymptomatic brain metastases that are equivocal or too small to warrant treatment may not be counted towards the above set limits upon discussion and agreement from the Medical Monitor.
- •Participant has an active medical illness(es) that, in the opinion of the Investigator, would pose increased risks for study participation.
- •Participants with non-small cell lung cancer with refractory and clinically significant pleural effusions.
- •Participant has any form of primary or acquired immunodeficiency.
- •Participant has a history of hypersensitivity to any component of the study intervention.
- •Participant had another primary malignancy within the previous 3 years (with protocol specified exceptions).
- •Participant has a history of allogeneic organ transplant, allogeneic cell therapy, or genetically engineered cell therapy. Prior engineered TIL cell therapy is allowed.
- •Participant requires systemic steroid therapy of greater than10 mg/day of prednisone or equivalent.
- •Participant received a live or attenuated vaccination within 28 days prior to the start of lymphodepletion (LD).
- •Participant has evidence of positive infectious disease screening and/or any active uncontrolled viral, bacterial, or fungal disease requiring ongoing systemic treatment or identified during screening.
研究组 & 干预措施
Participants with advanced solid tumors
Experimental
Participants will receive conditioning therapy prior to administration of OBX-115 regimen.
干预措施: OBX-115 (Biological)
结局指标
主要结局
Incidence and nature of dose-limiting toxicities (DLTs)
时间窗: 28 Days
• Incidence of dose-limiting toxicities (DLTs) during the first 28 days after OBX-115 infusion (Phase 1).
The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1
时间窗: 2 years
• The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by Blinded Independent Central Review (BICR) from the date of OBX-115 infusion until disease progression, death, start of a new anticancer therapy, withdrawal of consent, or end of study, whichever comes first (Phase 2 Cohort 3)
次要结局
- Incidence of AEs(2 years)
- The proportion of participants who have a confirmed CR or PR per RECIST v1.1(2 years)
研究者
研究点 (19)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic MelanomaMetastatic MelanomaTumorMelanomaNCT05470283M.D. Anderson Cancer Center21
已完成
1 期
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)Non-Hodgkin's LymphomaNCT02611323Hoffmann-La Roche133
已完成
1 期
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell LymphomaNCT02600897Hoffmann-La Roche114
已完成
2 期
ACVDL Treatment for Patients With Newly Diagnosed Multiple MyelomaMultiple MyelomaNCT01481194Vejle Hospital35
招募中
2 期
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee JointOsteo Arthritis KneeOsteoarthritisNCT06485843Ageless Biotech, Inc.400